While the Food and Drug Administration (FDA) in the USA and the Ministry of Health, Labour and Welfare in Japan have also approved anti-PD1 antibody in combination with chemotherapy as a first-line treatment for GC patients, its efficacy in those with peritoneal dissemination is not significantly pronounced [9, 12]. The gene discussed is PDCD1; the disease is gastric cancer.